Trial Profile

Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 05 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blarcamesine (Primary)
Indications Alzheimer's disease
Focus Adverse reactions
Acronyms ATTENTION-AD
Sponsors Anavex Life Sciences

Most Recent Events

09 Sep 2025 According to an Anavex Life Sciences media release, company will continue to evaluate the phase IIb/III early Alzheimer's disease and ATTENTION-AD trial data, which will be published and presented at international AD conferences.
09 Sep 2025 According to an Anavex Life Sciences media release, company announced today the latest findings for blarcamesine, for treatment of early Alzheimer's disease (AD).
09 Sep 2025 Results presented in a Anavex Life Sciences media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com